{"id":"adjuvanted-quadrivalent-influenza-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The vaccine contains four different influenza strains, each with a specific antigen that triggers an immune response. This immune response helps the body to recognize and fight off the influenza virus, reducing the risk of infection.","oneSentence":"This vaccine induces an immune response against multiple strains of influenza.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:19:46.338Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of influenza disease caused by four different strains of the influenza virus"}]},"trialDetails":[{"nctId":"NCT07485855","phase":"PHASE3","title":"Influenza Vaccination Strategy for Patients With Hematologic Malignancy","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-12-04","conditions":"Hematologic Neoplasms, Influenza, Immunogenicity","enrollment":60},{"nctId":"NCT06087640","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seqirus","startDate":"2023-10-23","conditions":"Influenza, Human","enrollment":35800},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT06279871","phase":"PHASE3","title":"Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-03-27","conditions":"COVID-19","enrollment":1514},{"nctId":"NCT05606965","phase":"PHASE2","title":"A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-02","conditions":"Influenza","enrollment":172},{"nctId":"NCT06125691","phase":"PHASE1","title":"Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-01-22","conditions":"Influenza, Human","enrollment":139},{"nctId":"NCT05291676","phase":"PHASE2","title":"Systems Investigation of Vaccine Responses in Aging and Frailty","status":"RECRUITING","sponsor":"Yale University","startDate":"2023-11-06","conditions":"Influenza","enrollment":96},{"nctId":"NCT06054269","phase":"PHASE3","title":"Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2022-11-04","conditions":"Influenza","enrollment":192},{"nctId":"NCT06015282","phase":"PHASE3","title":"The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-11-03","conditions":"Influenza, Human","enrollment":7741},{"nctId":"NCT03312699","phase":"PHASE1","title":"Effects of Aging on Primary and Secondary Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-09-19","conditions":"Influenza, Hepatitis A, Typhoid","enrollment":54},{"nctId":"NCT02871206","phase":"PHASE4","title":"Adjuvanted Inactivated Vaccine Versus Inactivated Influenza Vaccine in Hutterite Children","status":"COMPLETED","sponsor":"McMaster University","startDate":"2016-11","conditions":"Influenza","enrollment":3425},{"nctId":"NCT04782323","phase":"PHASE2","title":"Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2021-04-13","conditions":"Influenza","enrollment":839},{"nctId":"NCT05568797","phase":"PHASE3","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-14","conditions":"Respiratory Syncytial Virus Infections","enrollment":1045},{"nctId":"NCT05007041","phase":"PHASE4","title":"Simultaneous RZV and aIIV4 Vaccination","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-09-21","conditions":"Pain, Quality of Life, Injection Site Reaction","enrollment":267},{"nctId":"NCT04576702","phase":"PHASE2","title":"Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2020-10-08","conditions":"Influenza, Human","enrollment":471},{"nctId":"NCT05501561","phase":"PHASE2","title":"Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2022-08-25","conditions":"Influenza, Human","enrollment":1056},{"nctId":"NCT06304038","phase":"","title":"Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in Rome","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2017-10-16","conditions":"Influenza Vaccine, Cost-Benefit Analysis","enrollment":5483},{"nctId":"NCT05044195","phase":"PHASE3","title":"A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2021-09-30","conditions":"Influenza, Human","enrollment":2044},{"nctId":"NCT06029933","phase":"","title":"Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years","status":"RECRUITING","sponsor":"Kaiser Permanente","startDate":"2023-08-17","conditions":"Influenza, Community-acquired Pneumonia, Cardiovascular Events","enrollment":960000},{"nctId":"NCT04622592","phase":"PHASE1, PHASE2","title":"Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older","status":"COMPLETED","sponsor":"Medicago","startDate":"2020-11-02","conditions":"Influenza","enrollment":209},{"nctId":"NCT05082688","phase":"PHASE2","title":"Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2021-09-20","conditions":"Influenza, Herpes Zoster","enrollment":148},{"nctId":"NCT03669627","phase":"PHASE2","title":"CT18 Infant Influenza Priming Study in Vaccine Naive Infants","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2018-11-01","conditions":"Influenza","enrollment":159},{"nctId":"NCT01964989","phase":"PHASE3","title":"Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.","status":"COMPLETED","sponsor":"Seqirus","startDate":"2013-11","conditions":"Influenza Virus","enrollment":10644},{"nctId":"NCT02255409","phase":"PHASE3","title":"Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05","status":"COMPLETED","sponsor":"Seqirus","startDate":"2014-10","conditions":"Influenza","enrollment":607},{"nctId":"NCT04077424","phase":"PHASE4","title":"Senescent Immunity in Elders and Vaccine Responses (SILVER)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-10-21","conditions":"Flu Vaccine","enrollment":10},{"nctId":"NCT03698279","phase":"PHASE2","title":"Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-09","conditions":"Influenza","enrollment":665},{"nctId":"NCT03275389","phase":"PHASE1","title":"A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-08","conditions":"Influenza, Human","enrollment":470},{"nctId":"NCT03448705","phase":"PHASE1","title":"Safety of 4Fluart ID Suspension for Injection in Adult Subjects","status":"COMPLETED","sponsor":"Fluart Innovative Vaccine Ltd, Hungary","startDate":"2018-01-31","conditions":"Human Influenza","enrollment":36},{"nctId":"NCT01195779","phase":"PHASE2","title":"Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2010-09-30","conditions":"Influenza, Influenza Vaccines","enrollment":4},{"nctId":"NCT03318315","phase":"PHASE2","title":"Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-02-20","conditions":"Avian Influenza, Influenza, Influenza Immunisation","enrollment":149},{"nctId":"NCT03314662","phase":"PHASE3","title":"Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2017-10-17","conditions":"Influenza, Human","enrollment":1778},{"nctId":"NCT02587221","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2016-09-30","conditions":"Influenza","enrollment":6790},{"nctId":"NCT02768805","phase":"PHASE2","title":"Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Medicago","startDate":"2016-03-02","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":900},{"nctId":"NCT03701061","phase":"PHASE4","title":"Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-10-11","conditions":"Influenza A Subtype H5N1 Infection","enrollment":12},{"nctId":"NCT02236052","phase":"PHASE2","title":"Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly Population","status":"COMPLETED","sponsor":"Medicago","startDate":"2014-07-16","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":450},{"nctId":"NCT02831751","phase":"PHASE2","title":"Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults","status":"COMPLETED","sponsor":"Medicago","startDate":"2016-04","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":1001},{"nctId":"NCT02500680","phase":"PHASE1","title":"The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)","status":"UNKNOWN","sponsor":"Nova Immunotherapeutics Limited","startDate":"2015-07","conditions":"Influenza, Human","enrollment":102},{"nctId":"NCT02583256","phase":"PHASE3","title":"Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)","status":"COMPLETED","sponsor":"Seqirus","startDate":"2016-01-29","conditions":"Influenza","enrollment":1601}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fluad®"],"phase":"phase_2","status":"active","brandName":"Adjuvanted Quadrivalent Influenza Vaccine","genericName":"Adjuvanted Quadrivalent Influenza Vaccine","companyName":"ModernaTX, Inc.","companyId":"modernatx-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine induces an immune response against multiple strains of influenza. Used for Prevention of influenza disease caused by four different strains of the influenza virus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}